» Articles » PMID: 30897353

Harnessing Immunoproteostasis to Treat Neurodegenerative Disorders

Overview
Journal Neuron
Publisher Cell Press
Specialty Neurology
Date 2019 Mar 22
PMID 30897353
Citations 19
Authors
Affiliations
Soon will be listed here.
Abstract

Immunoproteostasis is a term used to reflect interactions between the immune system and the proteinopathies that are presumptive "triggers" of many neurodegenerative disorders. The study of immunoproteostasis is bolstered by several observations. Mutations or rare variants in genes expressed in microglial cells, known to regulate immune functions, or both can cause, or alter risk for, various neurodegenerative disorders. Additionally, genetic association studies identify numerous loci harboring genes that encode proteins of known immune function that alter risk of developing Alzheimer's disease (AD) and other neurodegenerative proteinopathies. Further, preclinical studies reveal beneficial effects and liabilities of manipulating immune pathways in various neurodegenerative disease models. Although there are concerns that manipulation of the immune system may cause more harm than good, there is considerable interest in developing immune modulatory therapies for neurodegenerative disorders. Herein, I highlight the promise and challenges of harnessing immunoproteostasis to treat neurodegenerative proteinopathies.

Citing Articles

Antagonizing Il10 and Il4 signaling via intracerebral decoy receptor expression attenuates Aβ accumulation.

Koller E, McFarland K, Angelle C, Howard J, Ryu D, Dillon K Acta Neuropathol Commun. 2025; 13(1):51.

PMID: 40055831 PMC: 11887169. DOI: 10.1186/s40478-025-01968-3.


Integrative proteomics identifies a conserved Aβ amyloid responsome, novel plaque proteins, and pathology modifiers in Alzheimer's disease.

Levites Y, Dammer E, Ran Y, Tsering W, Duong D, Abreha M Cell Rep Med. 2024; 5(8):101669.

PMID: 39127040 PMC: 11384960. DOI: 10.1016/j.xcrm.2024.101669.


miR155, TREM2, INPP5D: Disease stage and cell type are essential considerations when targeting clinical interventions based on mouse models of Alzheimer's amyloidopathy.

Gandy S, Ehrlich M J Neuroinflammation. 2023; 20(1):214.

PMID: 37749581 PMC: 10518910. DOI: 10.1186/s12974-023-02895-7.


Mechanistic insights into the role of herpes simplex virus 1 in Alzheimer's disease.

Feng S, Liu Y, Zhou Y, Shu Z, Cheng Z, Brenner C Front Aging Neurosci. 2023; 15:1245904.

PMID: 37744399 PMC: 10512732. DOI: 10.3389/fnagi.2023.1245904.


How Many Alzheimer-Perusini's Atypical Forms Do We Still Have to Discover?.

Donato L, Morda D, Scimone C, Alibrandi S, DAngelo R, Sidoti A Biomedicines. 2023; 11(7).

PMID: 37509674 PMC: 10377159. DOI: 10.3390/biomedicines11072035.


References
1.
Tung Y, Yeo G, ORahilly S, Coll A . Obesity and FTO: Changing Focus at a Complex Locus. Cell Metab. 2014; 20(5):710-718. DOI: 10.1016/j.cmet.2014.09.010. View

2.
Ombrello M, Remmers E, Sun G, Freeman A, Datta S, Torabi-Parizi P . Cold urticaria, immunodeficiency, and autoimmunity related to PLCG2 deletions. N Engl J Med. 2012; 366(4):330-8. PMC: 3298368. DOI: 10.1056/NEJMoa1102140. View

3.
Zhou Q, Lee G, Brady J, Datta S, Katan M, Sheikh A . A hypermorphic missense mutation in PLCG2, encoding phospholipase Cγ2, causes a dominantly inherited autoinflammatory disease with immunodeficiency. Am J Hum Genet. 2012; 91(4):713-20. PMC: 3484656. DOI: 10.1016/j.ajhg.2012.08.006. View

4.
Marsh S, Abud E, Lakatos A, Karimzadeh A, Yeung S, Davtyan H . The adaptive immune system restrains Alzheimer's disease pathogenesis by modulating microglial function. Proc Natl Acad Sci U S A. 2016; 113(9):E1316-25. PMC: 4780638. DOI: 10.1073/pnas.1525466113. View

5.
Nataf S, Anginot A, Vuaillat C, Malaval L, Fodil N, Chereul E . Brain and bone damage in KARAP/DAP12 loss-of-function mice correlate with alterations in microglia and osteoclast lineages. Am J Pathol. 2005; 166(1):275-86. PMC: 1602283. DOI: 10.1016/S0002-9440(10)62251-1. View